Merck & Co. Pays US$35 M Upfront for Kelun-Biotech’s ADC Oncology Drug

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 7 (Table of Contents)

Published: 29 Jul-2022

DOI: 10.3833/pdr.v2022.i7.2710     ISSN: 1756-7874

Section: Research & Development



In another effort to bolster its oncology portfolio, Merck & Co...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details